Forbes contributors publish independent expert analyses and insights. Joshua Cohen is a Boston-based writer who covers health policy. The treatment consisted of two cycles of immunotherapy before ...

Bristol Myers Squibb has won FDA approval for an injectable version of its blockbuster cancer immunotherapy Opdivo, a regulatory decision that gives patients a more convenient dosing option and ...

The pairing of two Bristol Myers Squibb immunotherapies is now permitted for the first-line treatment of two types of gastrointestinal cancers, after regulatory decisions handed out this past week ...

Saturday, Bristol-Myers Squibb Company (NYSE:BMY) released results from the Phase 3 CheckMate -8HW trial evaluating Opdivo (nivolumab) plus Yervoy (ipilimumab) compared to the investigator’s choice of ...

Opdivo (nivolumab) is a prescription drug approved to treat non-small cell lung cancer (NSCLC). Opdivo is available only as a brand-name medication. It’s not available in a generic version. Opdivo ...

The U.S. Food and Drug Administration (FDA) on Tuesday approved Bristol Myers Squibb & Co’s (NYSE:BMY) Opdivo (nivolumab) plus Yervoy (ipilimumab) as a first-line treatment of adult and pediatric ...

The KEYNOTE-671 trial showed a 71% 36-month overall survival rate with perioperative Keytruda, compared to 64% with placebo. FDA approvals for Keytruda, Imfinzi, and Opdivo in perioperative settings ...

Add Yahoo as a preferred source to see more of our stories on Google. The EC approval is based on the Phase II CheckMate-744 trial in classical Hodgkin Lymphoma patients. Credit: Saiful52 / ...

Bristol Myers Squibb is gunning for newly diagnosed unresectable liver cancer—again—after an immunotherapy setback five years ago. The dual immunotherapy combination of Opdivo and Yervoy showed it can ...

Immunotherapy, exemplified by Opdivo, enhances cancer treatment by targeting malignant cells using the immune system, offering a more precise approach than traditional therapies. The FDA approved ...

Different parts of Medicare can provide coverage for cancer treatments, including Opdivo. The coverage will depend on various factors, such as the phase of treatment and where a person receives ...

Colorectal cancer (CRC) is emerging as a critical health concern, particularly due to a concerning rise in diagnoses among younger individuals. Colorectal cancer (CRC), developing in the colon or ...